Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1GSK3AGSK3BHRH1HRH2HTR7IDH1IDH2IMPA1IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | GALR3 | O60755 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL15323416 | 0.98 | LMNA (0.41) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Citric Acid SCHEMBL29356844 | 0.98 | LMNA (0.41) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Citric Acid SCHEMBL15323746 | 0.96 | MEN1 (0.40) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Citric Acid SCHEMBL15323411 | 0.96 | MEN1 (0.40) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Citric Acid SCHEMBL15323939 | 0.95 | LMNA (0.39) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Citric Acid SCHEMBL15324015 | 0.95 | MEN1 (0.39) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Citric Acid SCHEMBL15323531 | 0.95 | MEN1 (0.39) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Citric Acid SCHEMBL2345397 | 0.95 | CA4 (0.52) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Citric Acid SCHEMBL2345393 | 0.93 | CA4 (0.50) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Citric Acid SCHEMBL15322509 | 0.93 | MEN1 (0.38) | LMNAMEN1KMT2ACYP3A4SLC5A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 901 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551441-B2 | Water soluble silicon-containing granulate | BIO MINERALS NV (BE) | 2026-02-17 | — | — | US | claimed |
| US-20260026538-A1 | COMPOSITIONS COMPRISING CHOLINE AND OMEGA-3 FATTY ACID TO NUTRITIONALLY ENHANCE FOOD PRODUCTS | INGENUITY FOODS, INC. (US) | 2026-01-29 | — | — | US | claimed |
| US-12426615-B2 | Compositions comprising choline and omega-3 fatty acid to nutritionally enhance food products | INGENUITY FOODS, INC. (US) | 2025-09-30 | — | — | US | claimed |
| CN-120022522-A | Drug-loaded microneedle, drug-loaded microneedle patch and electrically-controlled drug release microneedle system | 成都邦迈医创科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-119896763-A | Pasty biological tissue adhesive capable of being coated and preparation method and application thereof | 哈尔滨工业大学 | 2025-04-29 | — | — | CN | claimed |
| CN-119556538-A | Alkaline stripping liquid for silicon-based surface composite film and stripping method thereof | 湖北兴福电子材料股份有限公司 | 2025-03-04 | — | — | CN | claimed |
| US-20250059446-A1 | MULTIVALENT IONIC LIQUIDS AS PROCESS AIDS FOR BITUMEN EXTRACTION | STERLING SPECIALTY CHEMICALS HOLDING UK LIMITED (GB) | 2025-02-20 | — | — | US | claimed |
| US-20240425723-A1 | PAD-IN-A-BOTTLE CHEMICAL MECHANICAL PLANARIZATION POLISHING WITH COST-EFFECTIVE NON-POROUS SOLID POLISHING PADS | VERSUM MATERIALS US, LLC | 2024-12-26 | — | — | US | claimed |
| US-12171224-B2 | Choline salt and ammonium-free adjuvants for water conditioning and agricultural formulations | SPECIALTY OPERATIONS FRANCE (FR) | 2024-12-24 | — | — | US | claimed |
| CN-119144588-A | Choline chloride modified papain enhanced alpha s1-CN main epitope targeted degradation method | 中国海洋大学 | 2024-12-17 | — | — | CN | claimed |
| US-20010043957-A1 | Lypolytic composition | MANN MORRIS (US) | 2001-11-22 | — | — | US | claimed |
| US-20010021704-A1 | Pharmaceutical compositions for the treatment of tumor diseases | RHONE-POULENC RORER GMBH, KOLN (DE) | 2001-09-13 | — | — | US | claimed |
| US-6048728-A | PROPAGATING CELLS; CONTACTING CELLS WITH A CULTURE MEDIUM, WHEREIN SAID COMPONENTS ARE SUFFICIENT TO INCREASE THE CULTURES PRODUCTIVE SHELF LIFE BY MAINTAINING CELLS IN A PROPAGATION STATE | CHIRON CORPORATION (US) | 2000-04-11 | — | — | US | claimed |
| US-5939076-A | Composition and method for treating or alleviating migraine headaches | ALLOCCA TECHICAL, INC. (US) | 1999-08-17 | — | — | US | claimed |
| WO-1999023881-A1 | COMPOSITION AND METHOD FOR PREVENTING OR ALLEVIATING MIGRAINE HEADACHES | ALLOCCA TECHNICAL, INC. (US) | 1999-05-20 | — | — | WO | claimed |
| EP-0435911-B1 | CELL CULTURE MEDIUM FOR ENHANCED CELL GROWTH, CULTURE LONGEVITY AND PRODUCT EXPRESSION | CETUS ONCOLOGY CORP (US) | 1996-03-13 | — | — | EP | claimed |
| EP-0501776-A1 | Stabilization of subterranean formations | HALLIBURTON COMPANY (US) | 1992-09-02 | — | — | EP | claimed |
| US-5097904-A | Flow control agents in enhanced oil recovery | HALLIBURTON COMPANY (US) | 1992-03-24 | — | — | US | claimed |
| EP-0435911-A1 | CELL CULTURE MEDIUM FOR ENHANCED CELL GROWTH, CULTURE LONGEVITY AND PRODUCT EXPRESSION. | CETUS CORP (US) | 1991-07-10 | — | — | EP | claimed |
| WO-1990003430-A1 | CELL CULTURE MEDIUM FOR ENHANCED CELL GROWTH, CULTURE LONGEVITY AND PRODUCT EXPRESSION | CETUS CORPORATION (US) | 1990-04-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12171224-B2 | Choline salt and ammonium-free adjuvants for water conditioning and agricultural formulations | ACHE, PHOSPHO1, CHAT | MEN1 2734/4885LMNA 3927/4885KMT2A 504/4885 |
| US-12551441-B2 | Water soluble silicon-containing granulate | SI, GIPR, VIP | MEN1 2488/4885LMNA 1265/4885KMT2A 3323/4885 |
| US-20260026538-A1 | COMPOSITIONS COMPRISING CHOLINE AND OMEGA-3 FATTY ACID TO NUTRITIONALLY ENHANCE FOOD PRODUCTS | ELOVL3, ELOVL6, ELOVL1 | MEN1 3184/4885LMNA 1305/4885KMT2A 3388/4885 |
| US-20010021704-A1 | Pharmaceutical compositions for the treatment of tumor diseases | GLS, HOGA1, NDUFB5 | MEN1 950/4885LMNA 1473/4885KMT2A 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.